| Shareholdings as of 12 March 2025 |
| UBS Fund Management (Switzerland) AG | 5.61% |
| Swisscanto Fondsleitung | 3.06% |
| Lemanik Holding | 3.03% |
| Board of Directors as of 31 December 2024 | 1.66% |
| Executive Board as of 31 December 2024 | 0.66% |
| Other shareholders | 85.99% |
Free float amounts to 100%. The overview reflects the notifications pursuant to art. 22 FMIO-FINMA and is based on the number of shares outstanding at the time of the notification. Following this link you will find the disclosure notices published by DocMorris via the electronic publication platform of the SIX Swiss Exchange.
| Shares outstanding as of 31 December 2024 | 11,816,512 |
| Convertible Bond 2022-2026 (outstanding/nominal amount CHF 95m) | 1,908,541 |
| Convertible Bond 2024-2029 (outstanding/nominal amount CHF 200m) | 1,742,902 |
| Total shares (diluted) | 15,467,955 |
In connection with the issuance of the convertible bonds, DocMorris created a share lending facility of 3,018,579 registered shares to facilitate the hedging for bond holders. These cannot in any case be converted into actual share holdings and are registered as treasury shares. The number of outstanding shares as of 31 December 2024 was 11,816,512 (14,835,093 ./. 3,018,581 treasury shares).
Want to know more? Our Investor Relations team will be glad to answer any questions you may have about the DocMorris share and related capital market topics.
Additional contacts can be found here:
